Commerzbank Aktiengesellschaft FI Buys 9,811 Shares of Medtronic PLC $MDT

Commerzbank Aktiengesellschaft FI lifted its stake in Medtronic PLC (NYSE:MDT) by 33.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,167 shares of the medical technology company’s stock after acquiring an additional 9,811 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Medtronic were worth $3,731,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Brighton Jones LLC boosted its holdings in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC lifted its position in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after acquiring an additional 381 shares during the last quarter. Perigon Wealth Management LLC boosted its stake in Medtronic by 8.0% in the second quarter. Perigon Wealth Management LLC now owns 14,831 shares of the medical technology company’s stock valued at $1,293,000 after acquiring an additional 1,096 shares in the last quarter. Kathmere Capital Management LLC boosted its stake in Medtronic by 29.9% in the second quarter. Kathmere Capital Management LLC now owns 7,772 shares of the medical technology company’s stock valued at $677,000 after acquiring an additional 1,788 shares in the last quarter. Finally, Cove Private Wealth LLC grew its holdings in Medtronic by 11.0% in the second quarter. Cove Private Wealth LLC now owns 16,629 shares of the medical technology company’s stock worth $1,450,000 after purchasing an additional 1,650 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Sanford C. Bernstein increased their price objective on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a report on Wednesday, November 19th. UBS Group upped their price objective on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday, November 19th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a research report on Wednesday, November 19th. Fourteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Stock Down 0.4%

Shares of MDT stock opened at $100.98 on Friday. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The firm has a market capitalization of $129.45 billion, a PE ratio of 27.22, a P/E/G ratio of 2.66 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock’s 50-day simple moving average is $99.44 and its 200-day simple moving average is $95.28.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).